IgE binding to linear epitopes of Ara h 2 in peanut allergic preschool children undergoing oral Immunotherapy

Allergic DiseasesImmunotherapy

Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy

J Allergy Clin Immunol.

Patil SU, Steinbrecher J, Calatroni A, Smith N, Ma A, Ruiter B, Virkud Y, Schneider M, Shreffler WG

doi: 10.1016/j.jaci.2019.07.028.

Allergic DiseasesImmunotherapy

First Real-World Safety Analysis of Preschool Peanut Oral Immunotherapy

J Allergy Clin Immunol Pract.

Soller L, Abrams EM, Carr S, Kapur S, Rex GA, Leo S, Lidman PG, Yeung J, Vander Leek TK, McHenry M, Wong T, Cook VE, Hildebrand KJ, Gerstner TV, Mak R, Lee NJ, Cameron SB, Chan ES

doi: 10.1016/j.jaip.2019.04.010.

Allergic Diseases

Added diagnostic value of peanut component testing: a cross sectional study in Australian children

J Allergy Clin Immunol Pract.

Kaur N, Mehr S, Katelaris C, Wainstein B, Altavilla B, Saad R, Valerio C, Codarini M, Burton P, Perram F, Baumgart K, Barnes EH, Campbell DE

doi: 10.1016/j.jaip.

Allergic DiseasesImmunotherapy

Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study

Lancet.

Chinthrajah RS, Purington N, Andorf S, Long A, O'Laughlin KL, Lyu SC, Manohar M, Boyd SD, Tibshirani R, Maecker H, Plaut M, Mukai K, Tsai M, Desai M, Galli SJ, Nadeau KC

doi: 10.1016/S0140-6736(19)31793-3.

Allergic DiseasesImmunotherapy

Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial

Lancet Child Adolesc Health.

Hourihane JO, Beyer K, Abbas A, Fernández-Rivas M, Turner PJ, Blumchen K, Nilsson C, Ibáñez MD, Deschildre A, Muraro A, Sharma V, Erlewyn-Lajeunesse M, Zubeldia JM, De Blay F, Sauvage CD, Byrne A, Chapman J, Boralevi F, DunnGalvin A, O'Neill C, Norval D, Vereda A, Skeel B, Adelman DC, du Toit G

doi: 10.

Allergic Diseases

AR101 Oral Immunotherapy for Peanut Allergy

N Engl J Med.

PALISADE Group of Clinical Investigators, Vickery BP, Vereda A, Casale TB, Beyer K, du Toit G, Hourihane JO, Jones SM, Shreffler WG, Marcantonio A, Zawadzki R, Sher L, Carr WW, Fineman S, Greos L, Rachid R, Ibáñez MD, Tilles S, Assa’ad AH, Nilsson C, Rupp N, Welch MJ, Sussman G, Chinthrajah S, Blumchen K, Sher E, Spergel JM, Leickly FE, Zielen S, Wang J, Sanders GM, Wood RA, Cheema A, Bindslev-Jensen C, Leonard S, Kachru R, Johnston DT, Hampel FC Jr, Kim EH, Anagnostou A, Pongracic JA, Ben-Shoshan M, Sharma HP, Stillerman A, Windom HH, Yang WH, Muraro A, Zubeldia JM, Sharma V, Dorsey MJ, Chong HJ, Ohayon J, Bird JA, Carr TF, Siri D, Fernández-Rivas M, Jeong DK, Fleischer DM, Lieberman JA, Dubois AEJ, Tsoumani M, Ciaccio CE, Portnoy JM, Mansfield LE, Fritz SB, Lanser BJ, Matz J, Oude Elberink HNG, Varshney P, Dilly SG, Adelman DC, Burks AW

doi: 10.1056/NEJMoa1812856.

Allergic Diseases

Ovomucoid epitope-specific repertoire of IgE, IgG₄ , IgG₁ , IgA₁ and IgD antibodies in egg allergic children

Allergy.

Suprun M, Getts R, Grishina G, Tsuang A, Suárez-Fariñas M, Sampson HA

doi: 10.1111/all.14357.

RECOMMENDED

Allergic DiseasesImmunotherapy

Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial

JAMA.

Fleischer DM, Greenhawt M, Sussman G, Bégin P, Nowak-Wegrzyn A, Petroni D, Beyer K, Brown-Whitehorn T, Hebert J, Hourihane JO, Campbell DE, Leonard S, Chinthrajah RS, Pongracic JA, Jones SM, Lange L, Chong H, Green TD, Wood R, Cheema A, Prescott SL, Smith P, Yang W, Chan ES, Byrne A, Assa'ad A, Bird JA, Kim EH, Schneider L, Davis CM, Lanser BJ, Lambert R, Shreffler W

doi: 10.1001/jama.2019.1113.

Allergic DiseasesImmunotherapy

Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization

J Allergy Clin Immunol.

Kim EH, Yang L, Ye P, Guo R, Li Q, Kulis MD, Burks AW

doi: 10.1016/j.jaci.2019.07.030.

Related content

Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy

First Real-World Safety Analysis of Preschool Peanut Oral Immunotherapy

Added diagnostic value of peanut component testing: a cross sectional study in Australian children

Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study

Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial

AR101 Oral Immunotherapy for Peanut Allergy

Ovomucoid epitope-specific repertoire of IgE, IgG4 , IgG1 , IgA1 and IgD antibodies in egg allergic children

Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial

Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization

Ovomucoid epitope-specific repertoire of IgE, IgG₄ , IgG₁ , IgA₁ and IgD antibodies in egg allergic children